Short answer
Compass Therapeutics, Inc. (CMPX) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$25M
- −26.5% YoY · −37.3% QoQ
- EPS (diluted)
- −$0.13
- +7.1% YoY · −30.0% QoQ
Source: XBRL data from the Compass Therapeutics, Inc. (CMPX) Q2 2026 10-Q on SEC EDGAR. USD.
Compass Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0; no product-sale revenue, unchanged from prior-year quarter
- Net loss $25.154M vs $19.881M YoY; operating margin not applicable
- Tovecimig R&D $12.261M vs $8.112M, highest program spend
- Cash, equivalents and marketable securities $180M; operating cash use $32.007M vs $25.040M
- FDA feedback expected Q3 2026; potential BLA filing later this year for tovecimig
Risk Factors
- New forum-selection risk triggered by June 23, 2026 amended bylaws, requiring specified Delaware or Massachusetts courts
- Regulatory and compliance exposure from Securities Act claims restricted to Delaware or Massachusetts federal courts
- Macroeconomic risk from July 2026 U.S. tariffs of approximately 10%–12.5% on virtually all imports
- Operational risk from tariff-driven costs for active pharmaceutical ingredients, raw materials, laboratory equipment, and research materials
- Financing risk from deteriorating credit markets making debt or equity financing costlier, more dilutive, or unavailable
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Compass Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.